Endocrine Abstracts

Introduction: PATRO Adults is an ongoing, longitudinal, noninterventional study assessing the long-term safety and efficacy of Omnitrope® (Sandoz; recombinant human growth hormone [rhGH]), among adults with severe growth hormone deficiency (GHD) treated in routine clinical practice in European countries. Omnitrope® was approved by the European Medicines Agency (EMA) in 2006, representing the first biosimilar approved by the EMA. We report the la...

Introduction: Omnitrope® (Sandoz) is a recombinant human growth hormone (rhGH) and was the first biosimilar medicine approved by the European Medicines Agency. PATRO Adults is an international, longitudinal, non-interventional study of the long-term safety and efficacy of Omnitrope® in adults treated in routine clinical practice. The study provides data on the long-term safety of rhGH in adult patients with severe GH deficiency (GHD). Here we pr...